Hugues de The and colleagues report that TP53 status is a predictive factor for responsiveness in breast cancers to a dose-dense epirubicin-cyclophosphamide chemotherapy regimen, and suggests that this regimen might be well suited for patients with TP53 mutant tumors.
Everything published by PLoS Medicine is Open Access: freely available for anyone to read, download, redistribute and otherwise use, as long as the authorship is properly attributed.
Citation: Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, et al. (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicincyclophosphamide regimen. PLoS Med 4(3): e90.
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040090
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-04-03-de-the.pdf
CONTACT:
Hugues de The
CNRS UMR 7151
St. Louis Hospital
1 av. C. Vellefaux
Paris 75475
France
+33 1 53 72 21 91
+33 1 53 72 21 90 (fax)
dethe@paris7.jussieu.fr
PLOS Medicine